Clinical Trials Browser

Phase 1 × alectinib × Gastrointestinal × Clear all

NCT06354387 2026-03-19

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular